(E)-4-(4'-hydroxyphenyl)cinnamic acid | 862650-71-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-4-(4'-hydroxyphenyl)cinnamic acid
• 英文别名: (E)-3-(4''-Hydroxy-biphenyl-4-yl)-acrylic acid；(E)-3-[4-(4-hydroxyphenyl)phenyl]prop-2-enoic acid
• CAS: 862650-71-3
• 化学式: C₁₅H₁₂O₃
• 分子量: 240.258
• InChiKey: DSRUVGINFZPVRB-XCVCLJGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-4-(4'-hydroxyphenyl)cinnamic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 盐酸羟胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以13%的产率得到N-hydroxy-(E)-3-(4'-hydroxybiphenyl-4-yl)-acrylamide
  参考文献：
  名称：

  WO2007/383

  摘要：

  公开号：
• 作为产物：
  描述：

  4-羟基-4'-溴联苯 在 palladium diacetate 、 lithium hydroxide 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 为溶剂， 反应 31.0h， 生成 (E)-4-(4'-hydroxyphenyl)cinnamic acid
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of a New Series of Retinoid-Related Biphenyl-4-ylacrylic Acids Endowed with Antiproliferative and Proapoptotic Activity

  摘要：

  Atypical retinoids (AR) represent a class of proapoptotic agents with promising potential in the treatment of neoplastic diseases. In the present work 4'-hydroxybiphenyl-4-ylacrylic acids were studied as a novel series of AR. The synthesized compounds were evaluated for their antiproliferative activity in a human promyelocytic leukemia cell line (NB4) and in an ovarian carcinoma cell system including IGROV-1, carrying a functional wild-type p53, and a cisplatin-resistant subline, IGROV-1/Pt-1. The presence of a bulky lipophilic group at position 3' (adamantan-1-yl being the best) and the E configuration of the acrylic moiety appear essential for activity below 1 mu M. No substitution on the rings or on the double bond improved the activity. A qualitative correlation between the log P and molecular volume of the 3'-substituent and the antiproliferative activity was found. From the study of a few selected compounds, it appears that the presence of the carboxylic group is an essential requirement for apoptogenic properties but not for antiproliferative activity, this being maintained in amide derivatives. On the other hand, compounds able to induce apoptosis produced a detectable level of genotoxic damage. This observation supports the hypothesis that the genotoxic stress is a critical event mediating apoptosis induction by compounds of this class. Among the compounds investigated, E-3-(3'-adamantan-1-yl-4'-hydroxybiphenyl-4-yl)acrylic acid (2) was chosen for further investigation.

  DOI：

  10.1021/jm049440h

文献信息

• [EN] CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY<br/>[FR] HEXAPEPTIDES CYCLIQUES A ACTIVITE ANTIBIOTIQUE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1996011210A1

  公开（公告）日：1996-04-18

  (EN) This invention relates to new polypeptide compounds represented by formula (I), wherein R1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on $g(b)-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including $i(Pneumocystis carinii) infection (e.g. $i(Pneumocystis carinii) pneumonia) in a human being or an animal.(FR) L'invention porte sur de nouveaux composés de polypeptides représentés par la formule (I) dans laquelle R1 est tel que défini dans la description, ainsi que sur leurs sels pharmacocompatibles qui présentent des activités antimicrobiennes (et spécialement antifongiques), des activités inhibitrices de la $g(b)-1, 3-glucan synthase, sur leur procédé de préparation des préparations pharmaceutiques en contenant, et sur une méthode de traitement prophylactique et/ou thérapeutique de maladies infectieuses dont celles dues au $i(Pneumocystis carinii) (par exemple la pneumonie à $i(Pneumocystis carinii)) chez l'homme ou l'animal.

  该发明涉及由式(I)表示的新的多肽化合物，其中R1如描述中所定义，并且其药学上可接受的盐具有抗微生物活性（特别是抗真菌活性），对$g(b)-1,3-葡聚糖合酶的抑制活性，以及其制备方法，包含该化合物的药物组合物，以及用于人类或动物的感染性疾病（包括$ i（Pneumocystis carinii）感染，例如$ i（Pneumocystis carinii）肺炎）的预防和/或治疗方法。
• Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives
  申请人：Pisano Claudio

  公开号：US20080319082A1

  公开（公告）日：2008-12-25

  Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours.

  苯基联苯和苯基萘化合物带有羟肟基，具有抗肿瘤和抗血管生成活性。因此，这些化合物特别适用于治疗耐药性肿瘤。
• Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors
  作者：Sabrina Dallavalle、Raffaella Cincinelli、Raffaella Nannei、Lucio Merlini、Gabriella Morini、Sergio Penco、Claudio Pisano、Loredana Vesci、Marcella Barbarino、Valentina Zuco

  DOI：10.1016/j.ejmech.2008.11.005

  日期：2009.5

  A series of hydroxamic acid-based histone deacetylase (HDAC) inhibitors were designed on the basis of a model of the HDAC2 binding site and synthesized. They are characterized by a cinnamic spacer, capped with a substituted phenyl group. Modifications of the spacer are also reported. In an in vitro assay with the isoenzyme HDAC2, a good correlation of the activity with the docking energy was found. In human ovarian carcinoma IGROV-1 cells, selected compounds produced significant acetylation of p53 and alpha-tubulin. Most compounds showed an antiproliferative activity comparable to that of SAHA. At equitoxic concentrations, the tested compounds were more effective than SAHA in inducing apoptotic cell death. Compounds selected for in vivo evaluation exhibited a significant antitumor activity on three tumor models at well tolerated doses, thus suggesting a good therapeutic index. (C) 2008 Elsevier Masson SAS. All rights reserved.
• POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND ORIENTED FILM
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP2479170B1

  公开（公告）日：2018-01-03
• CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0788511B1

  公开（公告）日：2002-12-11